Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 17Thoracic 2Gastrointestinal 2Head & Neck 1Genitourinary 1Breast 1

Conditions

Esophageal Neoplasms 72Esophageal Squamous Cell Carcinoma 41Carcinoma, Non-Small-Cell Lung 32Stomach Neoplasms 31Colorectal Neoplasms 29Ovarian Neoplasms 25Pancreatic Neoplasms 21Adenocarcinoma Of Esophagus 16Breast Neoplasms 15Lung Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Sarcoma 10Neoplasm Metastasis 10Melanoma 10Liver Neoplasms 10Endometrial Neoplasms 10Colonic Neoplasms 9Neoplasms 8Hepatoblastoma 8Head and Neck Neoplasms 8Cholangiocarcinoma 8Carcinoma, Hepatocellular 8Uterine Cervical Neoplasms 7Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Carcinoma, Renal Cell 7Anus Neoplasms 7Rectal Neoplasms 6Carcinoma, Squamous Cell 6Testicular Neoplasms 5

Interventions

Hyperthermic Intraperitoneal Chemotherapy 17Cisplatin 12Oxaliplatin 10Cytoreduction Surgical Procedures 10Fluorouracil 9Paclitaxel 8Mitomycin 8Leucovorin 6Surgical Procedures, Operative 4Doxorubicin 3Observation 2Neoadjuvant Therapy 2Laparoscopy 2Indocyanine Green 2Docetaxel 2Control Groups 2Chemotherapy, Adjuvant 2Carboplatin 2Capecitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1sodium thiosulfate 1pembrolizumab 1nilotinib 1lobaplatin 1irinotecan sucrosofate 1genexol-PM 1durvalumab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × Carboplatin × Gastrointestinal × Clear all
NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡